Promentis Pharmaceuticals, Inc, announced today that Dr. Chad Beyer and Michael Neary will present key scientific data on SXC-2023, a novel activator of System xc-, at the annual Society for Neuroscience meeting taking place November 3-7, 2018 in San Diego, California.
MILWAUKEE, Wis., /PRNewswire/ -- Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing innovative therapies for neuropsychiatric disorders, announced today that Dr. Chad Beyer and Michael Neary will present key scientific data on SXC-2023, a novel activator of System xc-, at the annual Society for Neuroscience meeting taking place November 3-7, 2018 in San Diego, California. This presentation is scheduled for: About Promentis Pharmaceuticals For further information, please contact: Media Contact:
SOURCE Promentis Pharmaceuticals, Inc. |